#China #Shanghai #Antengene #ATG-037 #ATG-022

Antengene Raises Expectations with Upcoming ESMO 2026 Presentations

Antengene Corporation Limited is a pioneering global biotech firm that has made significant strides in developing innovative treatments for severe autoimmune diseases and various forms of cancer. The company recently made headlines announcing their clinical abstracts approved for poster presentations at the 2026 European Society for Medical Oncology (ESMO) Annual Congress. This prestigious event will take place from October 23rd to 27th, 2026, at the IFEMA MADRID Convention Center in Madrid, Spain.

The two treatments that will be highlighted during the congress include ATG-022, a Claudin 18.2 antibody-drug conjugate (ADC), and ATG-037, an oral CD73 small-molecule inhibitor. These presentations aim to provide insights into the efficacy and safety of these promising candidates in the pursuit of more effective cancer therapies.

Details of the Presentations

1. ATG-022 (Claudin 18.2 ADC)
- Title: ATG-022, a Claudin 18.2 ADC, in Advanced Gastric and Gastroesophageal Junction Cancer (CLINCH) Phase 2 Results
- Presentation Number: 2886P
- Date: October 25, 2026
- Time: 12:00 PM - 12:45 PM (Central European Time)

2. ATG-037 (Oral CD73 Small Molecule Inhibitor)
- Title: Efficacy and safety of ATG-037, an oral CD73 inhibitor, plus pembrolizumab in patients with checkpoint inhibitor resistant melanoma – Updated results from the STAMINA-01 trial
- Presentation Number: 2087P
- Date: October 24, 2026
- Time: 12:00 PM - 12:45 PM (Central European Time)

About Antengene's Innovation

Antengene, listed on the Hong Kong Stock Exchange under the symbol 6996.HK, has focused its research and development on creating first-in-class or best-in-class therapeutic options for patients with pressing medical needs. The company has successfully navigated the challenging landscape of drug development, moving candidates through various stages of clinical evaluation.

Among its investigational portfolio are remarkable drugs such as ATG-101, a bispecific antibody targeting PD-L1 and 4-1BB, and ATG-125, which is also a bispecific ADC targeting B7-H3. Notably, their AnTenGager® platform features innovative T cell engagers designed to optimize the immune system's ability to confront tumors.

Antengene has achieved impressive milestones, including 33 Investigational New Drug (IND) approvals secured across the U.S. and Asia, as well as securing New Drug Application (NDA) approvals in multiple Asia-Pacific markets. Their leading product, XPOVIO® (selinexor), is commercially available in various regions, publicly recognized for its role in addressing specific cancer types.

Conclusion

With the upcoming ESMO 2026 presentations, Antengene is positioned to showcase its commitment to advancing oncology treatments and pushing the boundaries of therapeutic capabilities. The insights shared during this congress will not only highlight the progress that Antengene has achieved but also reinforce the importance of innovation in the ongoing battle against cancer. As healthcare professionals and researchers gather to exchange knowledge, the focus will remain on the future of cancer treatment and how emerging drugs can potentially reshape patient outcomes.